A phase 1 study compared pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity between SB12, a proposed eculizumab biosimilar, and EU and US reference products (Soliris) in healthy adults.
A phase 1 study compared pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity between SB12, a proposed eculizumab biosimilar, and the European Union and United States reference products (Soliris) in healthy adults.
Eculizumab is a monoclonal antibody that binds to the terminal complement protein C5, inhibiting the complement pathway to reduce the risk of hemolysis and thrombosis in paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder.
The study, published in the International Journal of Clinical Pharmacology and Therapeutics, randomized 240 healthy subjects (95.8% male) to the biosimilar, reference product sourced from the United States, or reference product sourced from the EU. A single 300 mg dose of the study drug was delivered via intravenous infusion, and blood samples were taken multiple times throughout the following 64 days.
Pharmacokinetics and Pharmacodynamics
Overall, pharmacokinetic parameters, including the primary PK endpoint (area under the serum concentration-time curve from time zero to infinity [AUCinf]) and secondary PK endpoints were comparable between the 3 treatment groups. In comparisons between pairs of treatments, pharmacokinetic similarity was demonstrated, as the 90% confidence intervals of the geometric least squares means ratios of the primary and secondary PK endpoints were within the predefined bioequivalence margins of 80-125%.
To evaluate pharmacodynamics, terminal complement activity over time was measured. The authors explained that terminal complement activity was selected as the PD endpoint “based on the correlation with clinical outcome and the understanding of mechanism of action (MOA) in PNH patients.” They reported that the PD profile of the proposed biosimilar “was similar to known eculizumab profiles,” and terminal complement activity over time was similar between the 3 treatment groups.
Safety and Immunogenicity
Most subjects (68.8%) experienced treatment-emergent adverse events (TEAEs), 56 (70.0%) in the SB12 group, 52 (65.0%) in the EU reference product group, and 57 (71.3%) in the US reference product group. The proportions of TEAEs considered to be related to the study drugs were 31.3% in the biosimilar group, 21.3% in the EU reference product group, and 36.3% in the US reference product group.
The most frequent TEAE considered related to the study drug was headache. Infusion-related reactions, an AE of special interest, were reported by 7.5% of subjects in the SB12 group, 5.0% in the EU reference group, and 1.3% in the US reference group. Most adverse events were mild to moderate; 3 participants (one in each treatment group) experienced severe TEAEs, all of which were considered unrelated to the study drug.
The incidence of anti-drug antibodies (ADA) was comparable between groups, according to the authors. Following the infusion, ADAs were detected in 2.5%, 1.3%, and 0% of participants in the biosimilar, EU reference, and US reference groups. No neutralizing antibodies were detected in ADA-positive subjects.
The investigators concluded their results demonstrated pharmacokinetic bioequivalence of SB12 to the EU and US eculizumab reference products based on EMA and FDA requirements. Furthermore, that safety and pharmacodynamic profiles were comparable between the treatment groups. They added that their findings “represent an important contribution to the totality of evidence for supporting the biosimilarity of SB12 to its reference drugs, following the demonstration of analytical and functional similarity in extensive quality and non-clinical results”
Reference
Lee HA, Jang H, Jeong D, Kim Y, Fuhr R. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. Int J Clin Pharmacol Ther. 2022;60(6):269-279. doi:10.5414/CP204176.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
January 28th 2025Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a Russian study that expanded on a previous phase 3 study.
Biosimilar Teriparatide Matches Forteo in Safety and Fracture Risk
January 23rd 2025Biosimilar teriparatide has been shown to be as safe and effective as its reference product for osteoporosis treatment, potentially enabling significant cost savings in Japan’s health care system while addressing persistent misconceptions about biosimilar quality.